MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
and sales of...
$101,122K
Proceeds from exercise of
stock options
$13K
Proceeds from purchases
under the employee...
$4K
Proceeds from sales of
property, plant and...
$2,372K
Net cash provided by
investing activities
$87,278K
Net cash provided by
financing activities
$17K
Canceled cashflow
$16,216K
Net increase
(decrease) in cash, cash...
$3,987K
Canceled cashflow
$83,308K
Purchases of marketable
securities
$16,184K
Purchase of property,
plant and equipment
$32K
Impairment and disposal of
long-lived assets
$52,889K
Net income (loss)
$44,692K
Stock-based compensation
expense
$8,200K
Prepaid expenses and
other current assets
-$5,915K
Depreciation
$2,713K
Non-cash lease expense
$1,603K
Accounts payable
$1,445K
Termination of prepaid
contracts and other costs
$915K
Other non-current
assets
-$244K
Net cash used in
operating activities
-$83,308K
Canceled cashflow
$118,616K
Deferred revenue
-$144,122K
Lease liabilities,
net
-$32,654K
Accrued liabilities
-$23,221K
Net accretion of
discounts on marketable...
$1,254K
Other non-current
liabilities
-$366K
Purchase of net
(premiums) discounts on...
$307K
Back
Back
Cash Flow
source: myfinsight.com
IGM Biosciences, Inc. (IGMS)
IGM Biosciences, Inc. (IGMS)